| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1993) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | A04AA02 |
| UNII: | WZG3J2MCOL |
Structure
| InChI Key | MFWNKCLOYSRHCJ-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C18H24N4O |
| Molecular Weight | 312.42 |
| AlogP | 2.32 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 2.0 |
| Polar Surface Area | 50.16 |
| Molecular species | BASE |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 23.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| ANTAGONIST | Serotonin 3a (5-HT3a) receptor antagonist |
| Primary Target | |
|---|---|
| 5-HT3A |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Hydrolase
|
- | - | - | - | 2.147 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | -39.58-6.68 | |
|
Ion channel
Ligand-gated ion channel
5HT3 receptor
|
74-450 | 1760 | 0.19-0.9 | 0.2512-9.12 | 0.7 | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor alpha subunit
|
- | - | - | 38000 | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor beta subunit
|
- | - | - | 38000 | - | |
|
Ion channel
Voltage-gated ion channel
Potassium channels
Voltage-gated potassium channel
|
- | 3715.35-3801.89 | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC22 family of organic cation and anion transporters
|
- | 4300 | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC47 family of multidrug and toxin extrusion transporters
|
- | 311000 | - | - | 67 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Postoperative Nausea and Vomiting | 4 | D020250 | ClinicalTrials |
| Nausea | 4 | D009325 | ClinicalTrials |
| Neoplasms | 4 | D009369 | ClinicalTrials |
| Pain | 3 | D010146 | ClinicalTrials |
| Uterine Cervical Neoplasms | 3 | D002583 | ClinicalTrials |
| Carcinoma, Hepatocellular | 3 | D006528 | ClinicalTrials |
| Gastroparesis | 2 | D018589 | ClinicalTrials |
| Glioma | 2 | D005910 | ClinicalTrials |
| Lymphoma | 2 | D008223 | ClinicalTrials |
| Leukemia, Mast-Cell | 2 | D007946 | ClinicalTrials |
| Pruritus | 2 | D011537 | ClinicalTrials |
Related Entries
Scaffolds
Side Effects from Label
Side Effects (PT)
Adverse Reactions
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 109889-09-0 |
| ChEBI | 184693 |
| ChEMBL | CHEMBL289469 |
| FDA SRS | WZG3J2MCOL |
| Human Metabolome Database | HMDB15026 |
| Guide to Pharmacology | 2300 |
| PharmGKB | PA449809 |
| PubChem | 3510 |
| SureChEMBL | SCHEMBL445223 |
CONTENTS